IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-05-06 (hcplive.com)
Medicaid Unwinding Linked to Disrupted Chronic Medication Therapy in Youth
New research reveals Medicaid unwinding disrupts chronic medication access for young adults, risking health and treatment outcomes amid enrollment losses.
Read more
2025-04-14 (healthnews.pt)
Iqvia and Ema join the forces to combat medicine scarcity in Europe |
IQVIA, one of the leading global suppliers of Clinical Research and Health Intelligence services, announced the signing of a contract with the European Medicines Agency (EMA) to provide access to its owner databases of drug consumption.
Read more
2025-04-04 (natemat.pl)
Using the potential of prevention by the way to increase adherence in chronic diseases
On March 27, a historical event took place, the World Adherence Day was celebrated for the first time. It was a great opportunity for multi -threaded expert debate about solutions aimed at increasing Adherence among the population of people with chronic diseases. Experts from the environment spoke on this subject
Read more
2025-03-12 (finance-monthly.com)
Medochemie at the Forefront: Making Healthcare Affordable Across Continents
Access to affordable medication remains one of healthcare's most persistent global challenges. While medical science continues to advance treatments for numerous conditions, the ability to deliver these innovations to patients at accessible prices determines their real-world impact. Generic medicines have emerged as a fundamental solution to this challenge, accounting for…
Read more
2025-02-07 (ajmc.com)
Gains in Capability, Losses in Access to Primary Care After COVID-19
Better access and capability scores were associated with integrated practice ownership and participation in accountable care organizations.
Read more
2025-01-21 (mckinsey.com)
Blueprint to close the women's health gap: How to improve lives and economies for all
In this annual McKinsey report, we provide a comprehensive, global view of women's health and explore new opportunities to help close the gap.
Read more
2024-11-11 (naukawpolsce.pl)
Experts: in Poland, there are still many obstacles to access for cancer patients to innovative drugs
These conclusions come from the report entitled: "Barriers to access to innovative treatment in selected cancer diseases", which was presented on Friday at a press conference in Warsaw. Authors of the report commissioned by All.Can Polska (an initiative to improve oncological care in Poland)
Read more
2024-11-09 (rynekzdrowia.pl)
In Poland, there are still many obstacles to access of cancer patients to innovative drugs
In Poland, we are still observing long delays in access of cancer patients to modern pharmacotherapy, experts say. The waiting time for reimbursement of a drug from the moment of its registration in the EU is one of the longest among the Community countries.
Read more
2024-11-05 (cxodigitalpulse.com)
Karthik SM Joins Biocon Biologics as Vice President of Human Resources
Karthik SM has been appointed as the Vice President of Human Resources at Biocon Biologics, leveraging his extensive experience in ...
Read more
2024-10-12 (saludnews.net)
In the Dominican Republic, approving a medicine locally takes almost two years
Latin American patients wait an average of 4.7 years to access innovative or cutting-edge treatments. There is limited availability
Read more
2024-10-11 (revista-360grados.com)
Latin American patients wait an average of 4.7 years to access innovative or cutting-edge treatments
October 11, 2024. A drug approved by the United States regulatory agency (FDA) in October 2024 will only be available to the public in Latin American health systems in August 2029 (on average), according to the W.A.I.T Indicator study 2024.
Read more
2024-09-21 (atlasdasaude.pt)
1st edition of the “National Index of Access to Medical Devices” presented next week
The main objectives of this study, which has the scientific support of the Faculty of Pharmacy of the University of Lisbon and the technical support of the consultant IQVIA, are to map the hospital circuit for medical devices, characterize the process of acquiring medical devices in
Read more